Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten Biopharmaceuticals (Asia).
Global independent private equity fund Jeito Capital has closed its second fund, Jeito II, surpassing its target of €1bn ($1.2bn), thereby establishing a significant new milestone for investment in European Biopharma.
RoosterBio has entered an exclusive distributor partnership with MineBio Life Sciences to expand access to scalable, research-grade and current good manufacturing practice (cGMP)-grade mesenchymal stem cell (MSC) and exosome bioprocessing solutions across China.
Halozyme Therapeutics’ subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former’s Hypercon technology.
Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HealthCare Royalty Partners (HCRx) to support the planned launch of AD109.
Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, which represents $2.9bn in total transaction equity value.
Aspect Biosystems has secured a C$79m($56.6m) investment from the Government of Canada to support a C$280m multi-year project aimed at advancing its pipeline of bioengineered cellular medicines for endocrine and metabolic diseases.
Germany-based Merck KGaA (Merck) has completed its previously announced acquisition of the chromatography business of JSR Life Sciences.
Biocytogen has entered a strategic partnership with Sihuan Pharmaceutical to advance new therapeutics across several disease areas, including weight loss.
Symeres has entered a collaboration with Ambagon Therapeutics on molecular glue research in colorectal cancer, aiming to address diseases considered difficult to treat.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.